Ann Marie Pendergast, PhD, has received a two-year $150,000 Lung Cancer Research Foundation grant to continue her laboratory work “uncovering novel vulnerabilities to treat small cell lung cancer therapy resistance.”

Li Lan, MD, PhD, researches how cancer cells respond to DNA damage through DNA repair mechanisms. The major focus of her lab — previously situated at The Krantz Family Center for Cancer Research, Mass General Cancer Center — is drug development.

Brent Hanks, MD, PhD, is working to develop new pharmacologic and genetic strategies to overcome immunotherapy resistance and investigating the mechanisms that contribute to some immunotherapy-associated toxicities.

DCI's multi-disciplinary Breast Cancer Program convened another successful free community symposium on breast health and breast cancer, which included interactive info sessions, Q & A panels with DCI experts, and educational booths.

Community members, including cancer survivors and caregivers, learned about the latest clinical advances in treating kidney, prostate, and bladder cancers. In addition, the 50-year career of urologist William Berry, MD, was honored.

MD & MDiv grad Monica Bodd thinks a lot about the patient experience and how to make it better — both through research and clinical practice. You can take the doctor out of Duke, but you can't take Duke out of the doctor.

Umbilical cord blood-based cellular therapy could be lifesaver for patients without donor match .

DCI E-NEWS July 11, 2023: NASCAR Legend :: CRISPR :: NKTL :: Moore FAAN :: Good to Go :: Better with Age Worms

DCI E-NEWS June 9, 2023: Chemo Shortage :: ASCO :: Men’s Health :: Mom of the Year :: Melanoma Drivers :: Survivors

As the 2023 Annual Meeting of the American Society of Clinical Oncology was wrapping up this week, Chief Patient Experience and Safety Officer at Duke Cancer Institute Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO, was already in planning mode.

DCI E-NEWS May 2, 2023: Survivor Moms :: Cord Blood :: Fetal GBM :: Surgeon of the Year :: Rossi & Robotics

Omidubicel, a novel cellular therapy, expands the availability of donor stem cell transplants to more patients.